Annex I
United Kingdom
Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:
| Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp | |||||||||||||||||||
| Country | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol | Beclamethasone | Dexamethasone | Flunisolide | Fluticasone | Budesonide | Triamcinolone | Ipratropium bromide | Oxitropium bromide |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria |  | | | | | | | | | | | ||||||||
| Belgium | | | | | | | | | | | | ||||||||
| Cyprus | | ||||||||||||||||||
| Czech Republic | | | | | | | | | | | | ||||||||
| Denmark | | | | | | | | | | | |||||||||
| Estonia | | | | | | | | | | | | ||||||||
| Finland | | ||||||||||||||||||
| France | | ||||||||||||||||||
| Germany | | | | | | | | | | | | | | | | | | | |
| Greece | | | | | | | | | | | | ||||||||
| Hungary | | | | | | | | | | | | ||||||||
| Ireland | | ||||||||||||||||||
| Latvia | | | | | | | | | | | | ||||||||
| Lithuania | | | | | | | | | | | | ||||||||
| Luxembourg | | ||||||||||||||||||
| Poland | | ||||||||||||||||||
| Portugal | | | | | | | | | | | | ||||||||
| The Netherlands | | | | | | | | | | | | ||||||||
| Norway | | | | | | | | | | | | ||||||||
| Slovak Republic | | | | | | | | | | | | ||||||||
| Slovenia | | | | | | | | | | | | ||||||||
| Spain | | ||||||||||||||||||
| Sweden | | ||||||||||||||||||
| UK | | ||||||||||||||||||